Is STAAR Surgical (STAA) A Bargain Following Its Profit Turnaround And China Led Sales Rebound?
STAAR Surgical (STAA) reported a 111% year-over-year increase in net sales to $93.5M, with China contributing over half. Net income turned positive at $8.1M. Despite this, the stock is down 11.88% over 30 days and 16.62% over a year. The company has no debt and significant cash reserves. Analysts suggest it may be undervalued with a fair value estimate of $29.67.
How this was made
The 30-second read
Why it matters
The earnings surprise may attract value‑oriented investors, but the modest price reaction suggests caution.
Market read
First earnings report showing a profit swing; relevant for traders tracking small‑cap turnaround stories.
What to watch
Cash reserves are strong but the company has no debt, limiting upside without clear growth catalysts.
Background
Simply Wall St provides a fundamental analysis of STAAR Surgical's recent earnings turnaround.
Ticker impact
Quarterly net sales jumped 111% YoY to $93.5M and the company posted a $8.1M profit, reversing a prior loss.
Potential upside of 5‑10% if investors price in the turnaround.
Profit reversal is material, but the company remains small and the move has been muted so far.
Market effects
May signal improving demand for ophthalmic devices in China.
China sales now represent over 50% of revenue, highlighting regional exposure.
Limited to medical device niche; broader market impact minimal.
Counterpoint
China demand could falter, and the stock may remain volatile despite the earnings beat.
Key entities
- CompanySTAAR Surgical
Medical device maker focused on ophthalmic surgery.
